Suven Life Sciences soars on securing 2 product patents for its NCE

13 Oct 2014 Evaluate

Suven Life Sciences is currently trading at Rs. 187.75, up by 5.15 points or 2.82% from its previous closing of Rs. 182.60 on the BSE.

The scrip opened at Rs. 182.60 and has touched a high and low of Rs. 188.60 and Rs. 178.90 respectively. So far 86346 shares were traded on the counter.

The BSE group 'B ' stock of face value Rs. 1 has touched a 52 week high of Rs. 229.80 on 08-Sep-2014 and a 52 week low of Rs. 46.05 on 11-Oct-2013.

Last one week high and low of the scrip stood at Rs. 189.75 and Rs. 174.75 respectively. The current market cap of the company is Rs. 2112.85 crore.

The promoters holding in the company stood at 64.76% while Institutions and Non-Institutions held 1.42% and 33.82% respectively.

Suven Life Sciences’ drug discovery portfolio which has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators has secured the grant of one product patent from USA and one product patent from South Korea corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030.

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).

With these new patents, Suven has a total of nineteen granted patents from USA and fifteen granted patents from South Korea. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.

Suven Life Sciences Share Price

165.40 -3.05 (-1.81%)
18-Dec-2025 10:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1753.15
Dr. Reddys Lab 1265.70
Cipla 1496.85
Zydus Lifesciences 915.50
Lupin 2108.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×